mondoBIOTECH and Bachem agree long-term cooperation on the development of peptides to fight rare diseases

Stans and Bubendorf, Switzerland, September 24, 2009. mondoBIOTECH (mondoBIOTECH Holding AG; SIX: RARE) and Bachem (SIX: BANB) today announced the conclusion of a long-term cooperation. In the frame of the agreement with Interferon Medical Use SA in Collina d'Oro, Switzerland, a 100% affiliate of mondoBIOTECH Holding AG, Bachem provides its comprehensive know how on peptides and its longstanding experience in the manufacture of peptides and finished pharmaceutical products. Bachem will receive unlimited access to the comprehensive and further increasing number of development projects of mondoBIOTECH for the treatment of rare diseases. Bachem will be in charge of providing peptide based active ingredients required by mondoBIOTECH, sterile finished products to be used in clinical trials as well as the appropriate regulatory documents. Further, Bachem is entitled to produce current developmental orphan drugs for mondoBIOTECH, once approved.

“As a global company located in Switzerland, we very much look forward to the opportunity of jointly manufacturing products ‘made in Switzerland’ with Bachem, the world leader in peptides,” said Fabio Cavalli, CEO and Chief Business Architect of mondoBIOTECH.

Walter Isler, Head of Marketing and Sales at Bachem AG, commented: “The agreed cooperation is another step in our longstanding successful collaboration with mondoBIOTECH and offers Bachem additional market potential. On the basis of this agreement, Bachem gets access to a multitude of peptide projects and thereby also further broadens its competency in the manufacture of sterile finished products. Bachem is pleased to be strategic partner of mondoBIOTECH and to support the company in its fight against rare diseases.”

About rare disease
Currently about 7,000 rare diseases are known. Rare diseases are a heterogeneous group of diseases that manifest themselves in almost any organ and may have a systemic expression. Frequently it is debilitating diseases that require sophisticated treatment and care. They are a heavy burden for patients and their families and partly lead to death already during childhood or adolescence. According to the definition valid in Europe, a disease is “rare” when less than one out of 2,000 people suffers from a specific clinical syndrome. However, together these diseases by no means are a rare phenomenon: in the European Union about 27 to 36 million people are affected.

About mondoBIOTECH
mondoBIOTECH is an independent Swiss listed (mondoBIOTECH Holding AG SIX: RARE) internet-based research company focussed on the continuous review, selection and development of already known agents, primarily occurring naturally in the body (peptides and other immuno modulating substances), for the treatment of rare and neglected diseases. The company was selected Technology Pioneer 2008 by the World Economic Forum and strives to sustainably change the world of medicine for rare diseases to the better on the basis of its innovative idea.
About Bachem
Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.

For further questions, please contact:

mondoBIOTECH Holding AG
Fabio Cavalli, CEO & Chief Business Architect
Murgstrasse, 18 CH-6370 Stans
Phone +41 840 200 019
www.mondobiotech.com
media@mondobiotech.com

Bachem Holding AG
Stephan Schindler, CFO
Phone +41 61 935 2333
Fax +41 61 935 2324
www.bachem.com
ir@bachem.com